Sanofi SA · EURONEXT:SAN
Sanofi SA — Investor Day (March 2022)
17 slides from Sanofi SA's investor day presentation, Mar 29, 2022
Slide 1: Immunology Investor Event: Epidemiology
Immunology Investor Event Epidemiology Cambridge, MA March 29, 2022
Slide 2: Dupixent: Atopic Dermatitis Adult 18+
Dupixent: Atopic Dermatitis Adult 18+ Number of patients (thousands) Prevalence 8,174 7,136 1,416 16,726 Treated 5,722 5,231 1,038 11,991 Moderate-to-Severe 2,638 2,997 595 6,230 Biologics eligible 1,675 1,121 222 3,018 Moderate-to-Severe uncontrolled Treated with multiple systemic steroids Most in
Slide 3: Dupixent: Atopic Dermatitis Adolescents 12-17yo
Dupixent: Atopic Dermatitis Adolescents 12-17yo Number of patients (thousands) Prevalence 2,497 2,538 5,035 Treated 2,072 2,297 4,369 Moderate-to-Severe 968 1,015 1,983 Biologics eligible 389 345 734 Moderate-to-Severe uncontrolled Treated with multiple systemic steroids or Most in need 166 92 258 o
Slide 4: Dupixent: Atopic Dermatitis Child 6-11yo
Dupixent: Atopic Dermatitis Child 6-11yo Number of patients (thousands) Prevalence 2,457 2,853 5,310 Treated 1,985 2,305 4,290 Moderate-to-Severe 718 894 1,612 Uncontrolled 320 Moderate-to-Severe Assuming eligibility limited to severe uncontrolled in pediatric Biologics eligible 88 74 162 indication
Slide 5: Dupixent: Atopic Dermatitis Child <6yo
Dupixent: Atopic Dermatitis Child <6yo Number of patients (thousands) Prevalence 2,429 2,594 5,023 Treated 1,700 1,815 3,515 Moderate-to-Severe 675 777 1,452 Uncontrolled 261 Moderate-to-Severe Assuming eligibility limited to severe uncontrolled in pediatric Biologics eligible 75 80 155 indications.
Slide 6: Dupixent: Asthma 12+
Dupixent: Asthma 12+ Number of patients (thousands) Prevalence 23,500 18,420 4,900 46,820 Moderate to severe with persistent Treated 1,600 1,790 600 3,990 use of medium to high dose ICS or OCS use or biologic(2) Uncontrolled despite persistent use Biologics eligible 900 800 200 1,900 of medium to hi
Slide 7: Dupixent: Asthma 6-11yo
Dupixent: Asthma 6-11yo Number of patients (thousands) Prevalence 2,365 1,253 3,618 Moderate to severe with Treated 201 180 381 persistent use of medium to high dose ICS or OCS use or biologic Uncontrolled despite persistent Biologics eligible use of medium to high dose ICS 75 26 101 + ≥1 controller
Slide 8: Dupixent: Chronic Obstructive Pulmonary Disease
Dupixent: Chronic Obstructive Pulmonary Disease Number of patients (thousands) Prevalence 10,052 10,753 2,084 22,889 Treated 8,367 8,700 1,473 18,540 GOLD D 1,581 1,222 207 3,010 COPD with eosinophilic phenotype Eosinophilic population 300 200 50 550 uncontrolled with current SoC (patients that are
Slide 9: Dupixent: Chronic Rhinosinusitis with Nasal Polyposis
Dupixent: Chronic Rhinosinusitis with Nasal Polyposis Number of patients (thousands) Prevalence(1) 484 423 907 Treated 227 407 214 848 Moderate-to-Severe 147 191 147 485 Inadequately controlled Biologics eligible 90 74 43 207 CRSwNP(3) Patients uncontrolled Most in need 55 47 16 118 despite prior su
Slide 10: Dupixent: Chronic Rhinosinusitis Sans Nasal Polyposis
Dupixent: Chronic Rhinosinusitis Sans Nasal Polyposis Number of patients (thousands) Diagnosed CRSsNP Patients(1) 4,543 Diagnosed type 2 CRSsNP Patients 2,500 Most in need 130 0 500 1,000 1,500 2,000 2,500 3,000 3,500 4,000 4,500 5,000 US Source: Sanofi analysis (1) 12+ population 10 Immunology Inve
Slide 11: Dupixent: AFRS
Dupixent: AFRS Number of patients (thousands) Diagnosed CRSwNP 158 & had surgery(1) AFRS Patients 11 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 US Source: Sanofi analysis (1) 12+ population 11 Immunology Investor Event
Slide 12: Dupixent: Bullous Pemphigoid
Dupixent: Bullous Pemphigoid Number of patients (thousands) Prevalence(1) 52 50 19 121 Biologic eligible 27 26 10 63 Treated with systemic steroids 0 10 20 30 40 50 60 70 80 90 100 110 120 130 US Europe(2) Japan Source: Sanofi analysis OCS: Oral Corticosteroids (1) 18+ population (2) Germany, France
Slide 13: Dupixent: Prurigo Nodularis
Dupixent: Prurigo Nodularis Number of patients (thousands) Prevalence(1) 298 282 107 687 Patients inadequately controlled Biologic eligible 74 70 27 171 by topical corticosteroids 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 US Europe(2) Japan Source: Sanofi analysis (1) 18+ population (
Slide 14: Dupixent: Chronic Spontaneous Urticaria
Dupixent: Chronic Spontaneous Urticaria Number of patients (thousands) Prevalence(1) 1,500 551 2,051 Patients uncontrolled on Biologic eligible 308 110 418 anti-histamines and other SoC (excluding biologics) 0 200 400 600 800 1,000 1,200 1,400 1,600 1,800 2,000 2,200 US Japan Source: Sanofi analysis
Slide 15: Dupixent: Chronic Inducible Urticaria (Cold)
Dupixent: Chronic Inducible Urticaria (Cold) Number of patients (thousands) Prevalence(1) 160 25 Refractory to antihistamines Biologic eligible 0 20 40 60 80 100 120 140 160 180 US Source: Sanofi analysis (1) 12+ population 15 Immunology Investor Event
Slide 16: Dupixent: Chronic Pruritis of Unknown Origin
Dupixent: Chronic Pruritis of Unknown Origin Number of patients (thousands) 466 Prevalence(1) Treated 259 Treated with systemic therapy Biologic eligible 133 0 50 100 150 200 250 300 350 400 450 500 US Source: Sanofi analysis (1) 18+ population 16 Immunology Investor Event
Slide 17: Dupixent: Eosinophilic Esophagitis 12+
Dupixent: Eosinophilic Esophagitis 12+ Number of patients (thousands) Treated 159 161 320 Uncontrolled on high dose PPI and Severe 48 49 97 topical steroid slurry 0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 US Europe(1) Source: Sanofi analysis PPI = Proton pump inhibitor (1) German